The pharmaceutical giant Pfizer's decision to reduce its research and development of key employees at its facilities in Saint-Laurent in Montreal.
Tuesday at the unveiling of its financial results, Chairman and CEO of the American multinational, Ian Read, has announced plans to reduce its workforce by 5% worldwide. Pfizer hires 110,600 people.
A major research center in Sandwich, United Kingdom, which employs 2,400 people, will close. Another installation is particularly concerned, that of Groton in the U.S. state of Connecticut. Some 1,100 jobs will be eliminated.
At home, Pfizer has two research centers. The one in Ottawa, who is saved, and another in Montreal "is unfortunately affected by the ads," says the spokesperson of the Canadian pharmaceutical Julie-Catherine Racine. The center employs 150 people.
"It is too early to talk about impacts on the number of jobs since we are discussing the possibility of moving some operations to a strategic partner," says Racine.
Moreover, Pfizer has quadrupled its profits in the fourth quarter of 2010 versus the same period a year earlier. They were $ 2.89 billion. Its revenues rose 6% to $ 17.56 billion dollars.
Pfizer markets, including Viagra, the anti-inflammatory Celebrex and Ativan.